Brandon BioCatalyst
Overview
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, established to support the development and commercialization of early-stage biomedical discoveries. Managed by Brandon Capital, it is a unique collaboration involving major Australian superannuation funds, CSL, the Australian and New Zealand governments, state governments, and over 50 leading medical research institutes and hospitals. This partnership aims to advance the next generation of medical therapies and technologies to improve health and save lives. The firm focuses on a wide range of sectors within the life sciences, including biotechnology, healthcare, medical devices, pharmaceuticals, diagnostics, digital health, medical research, clinical trials, regenerative medicine, immunotherapy, oncology, neurology, cardiology, endocrinology, and infectious diseases. It invests across various stages, from seed funding to pre-IPO, providing both capital and expertise to guide the successful development of new therapies. Brandon BioCatalyst has supported more than 50 companies to date, partnering with talented scientists, clinicians, and entrepreneurs to bring innovative biomedical discoveries to market. Brandon BioCatalyst operates with a venture capital model that goes beyond providing investment; it partners with entrepreneurs to create businesses, run companies, and ensure the success of its investments. This approach includes offering non-dilutive grant funding, hands-on support, and access to global networks to new biotech spinouts emerging from academic research and small to medium-sized biotech enterprises with commercial potential. Through its initiatives, such as the CUREator program, it aims to transform promising biomedical research opportunities into clinical and market-ready solutions, benefiting patients and growing the Australian biotech ecosystem.
Investment Focus
- Early-stage biomedical discoveries
- Innovative medical therapies and technologies
- Companies with commercial potential in the life sciences sector
Portfolio Companies
Reach Brandon BioCatalyst directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Brandon BioCatalyst
What sectors does Brandon BioCatalyst invest in?
Brandon BioCatalyst invests in Healthcare, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Victoria, Australia. Brandon BioCatalyst is listed as a venture capital in the ConnectSafely investor database.
What stage does Brandon BioCatalyst invest at?
Brandon BioCatalyst backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage.
Which regions does Brandon BioCatalyst invest in?
Brandon BioCatalyst invests across Australia and New Zealand.
What companies has Brandon BioCatalyst invested in?
Brandon BioCatalyst's portfolio includes Pheon Therapeutics, CatalYm, NRG Therapeutics, Allay Therapeutics, QUE Oncology, Currus Biologics, Myricx Pharma and Glyscend.
Last updated · Source: ConnectSafely investor database